Shattuck Labs To Present Complete Dose-Escalation Data From Phase 1A Monotherapy Clinical Trial Of SL-172154 In Platinum-Resistant Ovarian Cancer At 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
Shattuck Labs will present complete dose-escalation data from its Phase 1A monotherapy clinical trial of SL-172154 in platinum-resistant ovarian cancer at the 2023 ASCO Meeting. SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose.
May 25, 2023 | 9:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shattuck Labs' SL-172154 shows promising results in Phase 1A clinical trial for platinum-resistant ovarian cancer, with favorable safety and tolerability profile. Presentation at 2023 ASCO Meeting.
Shattuck Labs' SL-172154 demonstrated favorable safety and tolerability profile in the Phase 1A clinical trial for platinum-resistant ovarian cancer. The presentation of these results at the 2023 ASCO Meeting will likely generate positive attention for the company and its stock, potentially leading to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100